bioMérieux S.A.

Paris Stock Exchange BIM.PA

bioMérieux S.A. Operating Income for the year ending December 31, 2023: USD 484.66 M

bioMérieux S.A. Operating Income is USD 484.66 M for the year ending December 31, 2023, a -19.08% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

bioMérieux S.A. Operating Income for the year ending December 31, 2022 was USD 598.95 M, a -31.49% change year over year.
bioMérieux S.A. Operating Income for the year ending December 31, 2021 was USD 874.25 M, a 29.84% change year over year.
bioMérieux S.A. Operating Income for the year ending December 31, 2020 was USD 673.33 M, a 81.32% change year over year.
bioMérieux S.A. Operating Income for the year ending December 31, 2019 was USD 371.35 M, a -10.74% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Paris Stock Exchange: BIM.PA

bioMérieux S.A.

CEO	Mr. Pierre Boulud
IPO Date	July 7, 2004
Location	France
Headquarters	376 Chemin De l'Orme
Employees	13,409
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Key trends

Past 5 years